Regulations and industry bodies are joining hands to simplify the process of drug development. But trials are becoming increasingly complex and the costs of drug development are increasing every day.
In this increasingly complex world, medical writers are striving to navigate their way through complex safety and regulatory documents and are leveraging technology and RWE to drive expedited submissions.
Nimita Limaye, PhD • Chief Executive Officer
Nymro Clinical Consultancy Services, India
Bindu Narang • Head, Regulatory Affairs and Aggregate Safety and Risk Management Practice
Sciformix Technologies Pvt. Ltd., India
Ashwini Patil • Expert Scientific Writer
Novartis Healthcare Pvt. Ltd., India
Rajesh Kher, PhD • Head of Outsourcing Partnership Management in the Capabilities group of IDAR
Janssen and Janssen Pharmaceutical Research & Development, L.L.C., India
Sofia Baig • Practice Lead - HEOR, PRMA & RWE
Tata Consultancy Services, India